{"id":"prazosin","rwe":[],"_fda":{"id":"08114092-fa12-4f58-b08e-03cadf9f726b","set_id":"08114092-fa12-4f58-b08e-03cadf9f726b","openfda":{"unii":["X0Z7454B90"],"route":["ORAL"],"rxcui":["198141","312593","312594"],"spl_id":["08114092-fa12-4f58-b08e-03cadf9f726b"],"brand_name":["Prazosin Hydrochloride"],"spl_set_id":["08114092-fa12-4f58-b08e-03cadf9f726b"],"package_ndc":["59651-271-01","59651-271-99","59651-272-01","59651-272-99","59651-273-01","59651-273-25"],"product_ndc":["59651-271","59651-272","59651-273"],"generic_name":["PRAZOSIN HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["PRAZOSIN HYDROCHLORIDE"],"manufacturer_name":["Aurobindo Pharma Limited"],"application_number":["ANDA213052"],"is_original_packager":[true]},"version":"1","warnings":["WARNINGS As with all alpha-blockers, prazosin hydrochloride may cause syncope with sudden loss of consciousness. In most cases, this is believed to be due to an excessive postural hypotensive effect, although occasionally the syncopal episode has been preceded by a bout of severe tachycardia with heart rates of 120 to 160 beats per minute. Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride. The incidence of syncopal episodes is approximately 1% in patients given an initial dose of 2 mg or greater. Clinical trials conducted during the investigational phase of this drug suggest that syncopal episodes can be minimized by limiting the initial dose of the drug to 1 mg, by subsequently increasing the dosage slowly, and by introducing any additional antihypertensive drugs into the patient’s regimen with caution (see DOSAGE AND ADMINISTRATION ) . Hypotension may develop in patients given prazosin hydrochloride who are also receiving a beta-blocker such as propranolol. If syncope occurs, the patient should be placed in the recumbent position and treated supportively as necessary. This adverse effect is self-limiting and in most cases does not recur after the initial period of therapy or during subsequent dose titration. Patients should always be started on the 1 mg capsules of prazosin hydrochloride. The 2 mg and 5 mg capsules are not indicated for initial therapy. More common than loss of consciousness are the symptoms often associated with lowering of the blood pressure, namely, dizziness and lightheadedness. The patient should be cautioned about these possible adverse effects and advised what measures to take should they develop. The patient should also be cautioned to avoid situations where injury could result should syncope occur during the initiation of prazosin hydrochloride therapy. Priapism Prolonged erections and priapism have been reported with alpha-1 blockers including prazosin in post marketing experience. In the event of an erection that persists longer than 4 hours, seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result."],"pregnancy":["Usage in Pregnancy: Pregnancy Category C. Prazosin hydrochloride has been shown to be associated with decreased litter size at birth, 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times and 12 times the usual maximum recommended human dose, respectively. The use of prazosin and a beta-blocker for the control of severe hypertension in 44 pregnant women revealed no drug-related fetal abnormalities or adverse effects. Therapy with prazosin was continued for as long as 14 weeks. 1 Prazosin has also been used alone or in combination with other hypotensive agents in severe hypertension of pregnancy by other investigators. No fetal or neonatal abnormalities have been reported with the use of prazosin. 2 There are no adequate and well controlled studies which establish the safety of prazosin hydrochloride in pregnant women. Prazosin hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus."],"overdosage":["OVERDOSAGE Accidental ingestion of at least 50 mg of prazosin hydrochloride in a two year old child resulted in profound drowsiness and depressed reflexes. No decrease in blood pressure was noted. Recovery was uneventful. Should overdosage lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used. Renal function should be monitored and supported as needed. Laboratory data indicate prazosin hydrochloride is not dialysable because it is protein bound."],"references":["References Lubbe, WF, and Hodge, JV: New Zealand Med J, 94 (691) 169–172, 1981. Davey, DA, and Dommisse, J: S.A. Med J , Oct. 4, 1980 (551–556). Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 Manufactured by: Aurobindo Pharma Limited Hyderabad–500 032, India Issued: February 2023"],"description":["DESCRIPTION Prazosin hydrochloride, a quinazoline derivative, is the first of a new chemical class of antihypertensives. It is the hydrochloride salt of 1-(4-amino-6, 7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine and its structural formula is: Molecular formula C 19 H 21 N 5 O 4 .HCl It is a white or almost white crystalline powder, very slightly soluble in water, slightly soluble in alcohol and methanol, practically insoluble in acetone and has a molecular weight of 419.87. Each 1 mg capsule of prazosin hydrochloride USP, for oral use contains drug equivalent to 1 mg free base. Prazosin hydrochloride capsules USP contains the following inactive ingredients: corn starch, magnesium stearate, sodium lauryl sulfate, sucrose. The hard gelatin capsules contain gelatin and titanium dioxide. In addition, the 1 mg hard gelatin capsules contain D&C Yellow 10 and FD&C Yellow 6; the 2 mg hard gelatin capsules contain D&C Yellow 10, FD&C Blue 1, FD&C Red 3 and FD&C Yellow 6; the 5 mg hard gelatin capsules contains D&C Yellow 10, FD&C Blue 1, FD&C Red 3 and FD&C Yellow 6. The capsule shells are imprinted with black ink which contains black iron oxide, potassium hydroxide and shellac. FDA approved dissolution test specifications differ from USP. Chemical Structure"],"precautions":["PRECAUTIONS General Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery. Information for Patients: Dizziness or drowsiness may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased. Dizziness, lightheadedness, or fainting may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking prazosin hydrochloride, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions. Drug Interactions Prazosin hydrochloride has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout– allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol ( see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories– propoxyphene, aspirin, indomethacin, and phenylbutazone. Addition of a diuretic or other antihypertensive agent to prazosin hydrochloride has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the prazosin hydrochloride dose to 1 mg to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating prazosin hydrochloride based on clinical response. Concomitant administration of prazosin hydrochloride with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION ) . Drug/Laboratory Test Interactions In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for pheochromocytoma in patients who are being treated with prazosin. If an elevated VMA is found, prazosin should be discontinued and the patient retested after a month. Laboratory Tests In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels. Carcinogenesis, Mutagenesis, Impairment of Fertility: No carcinogenic potential was demonstrated in an 18 month study in rats with prazosin hydrochloride at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day. Prazosin hydrochloride was not mutagenic in in vivo genetic toxicology studies. In a fertility and general reproductive performance study in rats, both males and females, treated with 75 mg/kg (225 times the usual maximum recommended human dose), demonstrated decreased fertility, while those treated with 25 mg/kg (75 times the usual maximum recommended human dose) did not. In chronic studies (one year or more) of prazosin hydrochloride in rats and dogs, testicular changes consisting of atrophy and necrosis occurred at 25 mg/kg/day (75 times the usual maximum recommended human dose). No testicular changes were seen in rats or dogs at 10 mg/kg/day (30 times the usual maximum recommended human dose). In view of the testicular changes observed in animals, 105 patients on long term prazosin hydrochloride therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. In addition, 27 males on prazosin hydrochloride for up to 51 months did not have changes in sperm morphology suggestive of drug effect. Usage in Pregnancy: Pregnancy Category C. Prazosin hydrochloride has been shown to be associated with decreased litter size at birth, 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times and 12 times the usual maximum recommended human dose, respectively. The use of prazosin and a beta-blocker for the control of severe hypertension in 44 pregnant women revealed no drug-related fetal abnormalities or adverse effects. Therapy with prazosin was continued for as long as 14 weeks. 1 Prazosin has also been used alone or in combination with other hypotensive agents in severe hypertension of pregnancy by other investigators. No fetal or neonatal abnormalities have been reported with the use of prazosin. 2 There are no adequate and well controlled studies which establish the safety of prazosin hydrochloride in pregnant women. Prazosin hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus. Nursing Mothers: Prazosin hydrochloride has been shown to be excreted in small amounts in human milk. Caution should be exercised when Prazosin hydrochloride is administered to a nursing woman. Usage in Children: Safety and effectiveness in children have not been established."],"how_supplied":["HOW SUPPLIED Prazosin Hydrochloride Capsules USP, 1 mg are yellow opaque cap and yellow opaque body, hard gelatin capsule shell imprinted “PRA” on cap and “1” on the body filled with white to off white granules. Bottles of 100 NDC 59651-271-01 Bottles of 1,000 NDC 59651-271-99 Prazosin Hydrochloride Capsules USP, 2 mg are yellow opaque cap and pink opaque body, hard gelatin capsule shell imprinted “PRA” on cap and “2” on the body filled with white to off white granules. Bottles of 100 NDC 59651-272-01 Bottles of 1,000 NDC 59651-272-99 Prazosin Hydrochloride Capsules USP, 5 mg are yellow opaque cap and blue opaque body, hard gelatin capsule shell imprinted “PRA” on cap and “5” on the body filled with white to off white granules. Bottles of 100 NDC 59651-273-01 Bottles of 250 NDC 59651-273-25 Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]."],"effective_time":"20230404","nursing_mothers":["Nursing Mothers: Prazosin hydrochloride has been shown to be excreted in small amounts in human milk. Caution should be exercised when Prazosin hydrochloride is administered to a nursing woman. Usage in Children: Safety and effectiveness in children have not been established."],"adverse_reactions":["ADVERSE REACTIONS Clinical trials were conducted on more than 900 patients. During these trials and subsequent marketing experience, the most frequent reactions associated with prazosin hydrochloride therapy are: dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, and nausea 4.9%. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in dose of drug. Less frequent adverse reactions which are reported to occur in 1 to 4% of patients are: Gastrointestinal: vomiting, diarrhea, constipation. Cardiovascular: edema, orthostatic hypotension, dyspnea, syncope. Central Nervous System: vertigo, depression, nervousness. Dermatologic: rash. Genitourinary: urinary frequency. EENT: blurred vision, reddened sclera, epistaxis, dry mouth, nasal congestion. In addition, fewer than 1% of patients have reported the following (in some instances, exact causal relationships have not been established): Gastrointestinal: abdominal discomfort and/or pain, liver function abnormalities, pancreatitis. Cardiovascular: tachycardia. Central Nervous System: paresthesia, hallucinations. Dermatologic: pruritus, alopecia, lichen planus. Genitourinary: incontinence, impotence, priapism. EENT: tinnitus. Other: diaphoresis, fever, positive ANA titer, arthralgia. Single reports of pigmentary mottling and serous retinopathy, and a few reports of cataract development or disappearance have been reported. In these instances, the exact causal relationship has not been established because the baseline observations were frequently inadequate. In more specific slit-lamp and funduscopic studies, which included adequate baseline examinations, no drug-related abnormal ophthalmological findings have been reported. Literature reports exist associating prazosin hydrochloride therapy with a worsening of pre-existing narcolepsy. A causal relationship is uncertain in these cases. In post-marketing experience, the following adverse events have been reported: Autonomic Nervous System: flushing. Body As A Whole: allergic reaction, asthenia, malaise, pain. Cardiovascular, General: angina pectoris, hypotension. Endocrine: gynecomastia. Heart Rate/Rhythm: bradycardia. Psychiatric: insomnia. Skin/Appendages: urticaria. Vascular (Extracardiac): vasculitis. Vision: eye pain. Special Senses: During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha-1 blocker therapy (see PRECAUTIONS ) ."],"contraindications":["CONTRAINDICATIONS Prazosin hydrochloride capsules are contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients."],"drug_interactions":["Drug Interactions Prazosin hydrochloride has been administered without any adverse drug interaction in limited clinical experience to date with the following: (1) cardiac glycosides– digitalis and digoxin; (2) hypoglycemics–insulin, chlorpropamide, phenformin, tolazamide, and tolbutamide; (3) tranquilizers and sedatives–chlordiazepoxide, diazepam, and phenobarbital; (4) antigout– allopurinol, colchicine, and probenecid; (5) antiarrhythmics–procainamide, propranolol ( see WARNINGS however), and quinidine; and (6) analgesics, antipyretics and anti-inflammatories– propoxyphene, aspirin, indomethacin, and phenylbutazone. Addition of a diuretic or other antihypertensive agent to prazosin hydrochloride has been shown to cause an additive hypotensive effect. This effect can be minimized by reducing the prazosin hydrochloride dose to 1 mg to 2 mg three times a day, by introducing additional antihypertensive drugs cautiously, and then by retitrating prazosin hydrochloride based on clinical response. Concomitant administration of prazosin hydrochloride with a phosphodiesterase-5 (PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see DOSAGE AND ADMINISTRATION ) ."],"general_precautions":["General Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients treated with alpha-1 blockers. This variant of small pupil syndrome is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs, and potential prolapse of the iris toward the phacoemulsification incisions. The patient’s ophthalmologist should be prepared for possible modifications to the surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances. There does not appear to be a benefit of stopping alpha-1 blocker therapy prior to cataract surgery."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY The exact mechanism of the hypotensive action of prazosin is unknown. Prazosin causes a decrease in total peripheral resistance and was originally thought to have a direct relaxant action on vascular smooth muscle. Recent animal studies, however, have suggested that the vasodilator effect of prazosin is also related to blockade of postsynaptic alpha-adrenoceptors. The results of dog forelimb experiments demonstrate that the peripheral vasodilator effect of prazosin is confined mainly to the level of the resistance vessels (arterioles). Unlike conventional alpha-blockers, the antihypertensive action of prazosin is usually not accompanied by a reflex tachycardia. Tolerance has not been observed to develop in long term therapy. Hemodynamic studies have been carried out in man following acute single dose administration and during the course of long term maintenance therapy. The results confirm that the therapeutic effect is a fall in blood pressure unaccompanied by a clinically significant change in cardiac output, heart rate, renal blood flow and glomerular filtration rate. There is no measurable negative chronotropic effect. In clinical studies to date, prazosin hydrochloride has not increased plasma renin activity. In man, blood pressure is lowered in both the supine and standing positions. This effect is most pronounced on the diastolic blood pressure. Following oral administration, human plasma concentrations reach a peak at about three hours with a plasma half-life of two to three hours. The drug is highly bound to plasma protein. Bioavailability studies have demonstrated that the total absorption relative to the drug in a 20% alcoholic solution is 90%, resulting in peak levels approximately 65% of that of the drug in solution. Animal studies indicate that prazosin hydrochloride is extensively metabolized, primarily by demethylation and conjugation, and excreted mainly via bile and feces. Less extensive human studies suggest similar metabolism and excretion in man. In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels."],"indications_and_usage":["INDICATIONS AND USAGE Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents."],"information_for_patients":["Information for Patients: Dizziness or drowsiness may occur after the first dose of this medicine. Avoid driving or performing hazardous tasks for the first 24 hours after taking this medicine or when the dose is increased. Dizziness, lightheadedness, or fainting may occur, especially when rising from a lying or sitting position. Getting up slowly may help lessen the problem. These effects may also occur if you drink alcohol, stand for long periods of time, exercise, or if the weather is hot. While taking prazosin hydrochloride, be careful in the amount of alcohol you drink. Also, use extra care during exercise or hot weather, or if standing for long periods. Check with your physician if you have any questions."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The dose of prazosin hydrochloride capsules should be adjusted according to the patient’s individual blood pressure response. The following is a guide to its administration: Initial Dose 1 mg two or three times a day (see WARNINGS. ) Maintenance Dose Dosage may be slowly increased to a total daily dose of 20 mg given in divided doses. The therapeutic dosages most commonly employed have ranged from 6 mg to 15 mg daily given in divided doses. Doses higher than 20 mg usually do not increase efficacy, however a few patients may benefit from further increases up to a daily dose of 40 mg given in divided doses. After initial titration some patients can be maintained adequately on a twice daily dosage regimen. Use With Other Drugs When adding a diuretic or other antihypertensive agent, the dose of prazosin hydrochloride capsules should be reduced to 1 mg or 2 mg three times a day and retitration then carried out. Concomitant administration of prazosin hydrochloride capsules with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking prazosin hydrochloride capsules."],"spl_product_data_elements":["Prazosin Hydrochloride Prazosin Hydrochloride PRAZOSIN HYDROCHLORIDE PRAZOSIN STARCH, CORN MAGNESIUM STEARATE SODIUM LAURYL SULFATE SUCROSE GELATIN, UNSPECIFIED TITANIUM DIOXIDE D&C YELLOW NO. 10 FD&C YELLOW NO. 6 FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE SHELLAC yellow opaque cap yellow opaque body PRA;1 Prazosin Hydrochloride Prazosin Hydrochloride PRAZOSIN HYDROCHLORIDE PRAZOSIN STARCH, CORN MAGNESIUM STEARATE SODIUM LAURYL SULFATE SUCROSE GELATIN, UNSPECIFIED TITANIUM DIOXIDE D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C RED NO. 3 FD&C YELLOW NO. 6 FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE SHELLAC yellow opaque cap pink opaque body PRA;2 Prazosin Hydrochloride Prazosin Hydrochloride PRAZOSIN HYDROCHLORIDE PRAZOSIN STARCH, CORN MAGNESIUM STEARATE SODIUM LAURYL SULFATE SUCROSE GELATIN, UNSPECIFIED TITANIUM DIOXIDE D&C YELLOW NO. 10 FD&C BLUE NO. 1 FD&C RED NO. 3 FD&C YELLOW NO. 6 FERROSOFERRIC OXIDE POTASSIUM HYDROXIDE SHELLAC yellow opaque cap blue opaque body PRA;5"],"package_label_principal_display_panel":["PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 mg (100 Capsules Bottle) NDC 59651-271-01 Rx only Prazosin Hydrochloride Capsules, USP 1 mg* AUROBINDO 100 Capsules PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 1 mg (100 Capsules Bottle)","PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 mg (100 Capsules Bottle) NDC 59651-272-01 Rx only Prazosin Hydrochloride Capsules, USP 2 mg* AUROBINDO 100 Capsules PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 2 mg (100 Capsules Bottle)","PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (100 Capsules Bottle) NDC 59651-273-01 Rx only Prazosin Hydrochloride Capsules, USP 5 mg* AUROBINDO 100 Capsules PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 5 mg (100 Capsules Bottle)"],"drug_and_or_laboratory_test_interactions":["Drug/Laboratory Test Interactions In a study on five patients given from 12 to 24 mg of prazosin per day for 10 to 14 days, there was an average increase of 42% in the urinary metabolite of norepinephrine and an average increase in urinary VMA of 17%. Therefore, false positive results may occur in screening tests for pheochromocytoma in patients who are being treated with prazosin. If an elevated VMA is found, prazosin should be discontinued and the patient retested after a month. Laboratory Tests In clinical studies in which lipid profiles were followed, there were generally no adverse changes noted between pre-and post-treatment lipid levels."],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility: No carcinogenic potential was demonstrated in an 18 month study in rats with prazosin hydrochloride at dose levels more than 225 times the usual maximum recommended human dose of 20 mg per day. Prazosin hydrochloride was not mutagenic in in vivo genetic toxicology studies. In a fertility and general reproductive performance study in rats, both males and females, treated with 75 mg/kg (225 times the usual maximum recommended human dose), demonstrated decreased fertility, while those treated with 25 mg/kg (75 times the usual maximum recommended human dose) did not. In chronic studies (one year or more) of prazosin hydrochloride in rats and dogs, testicular changes consisting of atrophy and necrosis occurred at 25 mg/kg/day (75 times the usual maximum recommended human dose). No testicular changes were seen in rats or dogs at 10 mg/kg/day (30 times the usual maximum recommended human dose). In view of the testicular changes observed in animals, 105 patients on long term prazosin hydrochloride therapy were monitored for 17-ketosteroid excretion and no changes indicating a drug effect were observed. In addition, 27 males on prazosin hydrochloride for up to 51 months did not have changes in sperm morphology suggestive of drug effect."]},"tags":[{"label":"alpha-Adrenergic Blocker","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1A adrenergic receptor","category":"target"},{"label":"ADRA1A","category":"gene"},{"label":"ADRA1D","category":"gene"},{"label":"ADRA1B","category":"gene"},{"label":"C02CA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Pfizer","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-1 Receptor Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":133.101,"date":"","count":27,"signal":"Analgesic drug level above therapeutic","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=133)"},{"llr":121.376,"date":"","count":27,"signal":"Antidepressant drug level above therapeutic","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=121)"},{"llr":86.059,"date":"","count":40,"signal":"Atrioventricular block first degree","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=86)"},{"llr":82.244,"date":"","count":84,"signal":"Suicidal ideation","source":"DrugCentral FAERS","actionTaken":"Reported 84 times (LLR=82)"},{"llr":82.134,"date":"","count":129,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 129 times (LLR=82)"},{"llr":71.157,"date":"","count":19,"signal":"Parasomnia","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=71)"},{"llr":67.092,"date":"","count":27,"signal":"Sudden cardiac death","source":"DrugCentral FAERS","actionTaken":"Reported 27 times (LLR=67)"},{"llr":65.857,"date":"","count":25,"signal":"Priapism","source":"DrugCentral FAERS","actionTaken":"Reported 25 times (LLR=66)"},{"llr":63.957,"date":"","count":42,"signal":"Sinus bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=64)"},{"llr":63.487,"date":"","count":170,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 170 times (LLR=63)"},{"llr":55.632,"date":"","count":39,"signal":"Posterior reversible encephalopathy syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 39 times (LLR=56)"},{"llr":51.155,"date":"","count":66,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 66 times (LLR=51)"},{"llr":45.28,"date":"","count":158,"signal":"Hypotension","source":"DrugCentral FAERS","actionTaken":"Reported 158 times (LLR=45)"},{"llr":44.037,"date":"","count":18,"signal":"Systolic dysfunction","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=44)"},{"llr":43.797,"date":"","count":18,"signal":"Suicidal behaviour","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=44)"}],"drugInteractions":[{"drug":"cardiac glycosides (digitalis, digoxin)","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No adverse drug interaction reported"},{"drug":"hypoglycemics (insulin, chlorpropamide, phenformin, tolazamide, tolbutamide)","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No adverse drug interaction reported"},{"drug":"tranquilizers and sedatives (chlordiazepoxide, diazepam, phenobarbital)","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No adverse drug interaction reported"},{"drug":"antigout (allopurinol, colchicine, probenecid)","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No adverse drug interaction reported"},{"drug":"antiarrhythmics (procainamide, propranolol, quinidine)","severity":"minor","mechanism":"Not specified","management":"No specific management required, caution advised with propranolol","clinicalEffect":"No adverse drug interaction reported (see WARNINGS for propranolol)"},{"drug":"analgesics, antipyretics, and anti-inflammatories (propoxyphene, aspirin, indomethacin, phenylbutazone)","severity":"minor","mechanism":"Not specified","management":"No specific management required","clinicalEffect":"No adverse drug interaction reported"},{"drug":"diuretics or other antihypertensive agents","severity":"major","mechanism":"Additive hypotensive effect","management":"Reduce prazosin hydrochloride dose to 1 mg to 2 mg three times a day, introduce additional antihypertensive drugs cautiously, and retitrate prazosin hydrochloride based on clinical response","clinicalEffect":"Additive hypotensive effect"},{"drug":"phosphodiesterase-5 (PDE-5) inhibitors","severity":"major","mechanism":"Additive blood pressure lowering effects","management":"See DOSAGE AND ADMINISTRATION for guidance","clinicalEffect":"Symptomatic hypotension"}],"commonSideEffects":[{"effect":"dizziness","drugRate":"10.3%","_validated":true,"placeboRate":""},{"effect":"headache","drugRate":"7.8%","_validated":true,"placeboRate":""},{"effect":"drowsiness","drugRate":"7.6%","_validated":true,"placeboRate":""},{"effect":"lack of energy","drugRate":"6.9%","_validated":true,"placeboRate":""},{"effect":"weakness","drugRate":"6.5%","_validated":true,"placeboRate":""},{"effect":"palpitations","drugRate":"5.3%","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"4.9%","_validated":true,"placeboRate":""}],"contraindications":["Prazosin hydrochloride capsules are contraindicated in patients with known sensitivity to quinazolines, prazosin, or any of the inert ingredients."],"specialPopulations":{"Pregnancy":"Pregnancy Category C. Prazosin hydrochloride has been shown to be associated with decreased litter size at birth, 1, 4, and 21 days of age in rats when given doses more than 225 times the usual maximum recommended human dose. No evidence of drug-related external, visceral, or skeletal fetal abnormalities were observed. No drug-related external, visceral, or skeletal abnormalities were observed in fetuses of pregnant rabbits and pregnant monkeys at doses more than 225 times a","Paediatric use":"Safety and effectiveness in children have not been established."}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1472/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$54","description":"PRAZOSIN 1 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PRAZOSIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:10:49.222015+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T03:12:03.274421+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:10:54.842784+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PRAZOSIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:10:55.527801+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:10:47.931707+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:57.088133+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:10:47.931726+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Adrenergic receptor alpha-1 antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:10:56.619656+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:52.270285+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1558/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:10:56.240066+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS Clinical trials were conducted on more than 900 patients. During these trials and subsequent marketing experience, the most frequent reactions associated with prazosin hydrochloride therapy are: dizziness 10.3%, headache 7.8%, drowsiness 7.6%, lack of energy 6.9%, weakness 6.5%, palpitations 5.3%, and nausea 4.9%. In most instances, side effects have disappeared with continued therapy or have been tolerated with no decrease in dose of drug. Less frequent adverse reactions which","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:08.794829+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:11:15.586159+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA213052","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:10:47.931730+00:00"}},"allNames":"minipress","offLabel":[],"synonyms":["prazosin","prazosin hydrochloride","furazosin","prazosin HCl"],"timeline":[{"date":"1976-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from PFIZER to Pfizer"},{"date":"1976-06-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Pfizer)"},{"date":"1992-01-29","type":"positive","source":"FDA Orange Book","milestone":"Minipress Xl approved — 2.5MG"},{"date":"2021-12-23","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 9 manufacturers approved"}],"aiSummary":"Prazosin (Minipress), marketed by Pfizer, is an established hypertension treatment with a key composition patent expiring in 2028. Its mechanism of action, targeting the alpha-1A adrenergic receptor, provides a distinct therapeutic profile for relaxing blood vessels and reducing blood pressure. The primary risk is competition from off-patent drugs like doxazosin, which has 18 generics available since its FDA approval in 1990.","approvals":[{"date":"1976-06-23","orphan":false,"company":"PFIZER","regulator":"FDA"}],"brandName":"Minipress","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null}],"mechanism":{"target":"Alpha-1A adrenergic receptor","novelty":"Follow-on","targets":[{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1D","source":"DrugCentral","target":"Alpha-1D adrenergic receptor","protein":"Alpha-1D adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"ADORA3","source":"DrugCentral","target":"Adenosine receptor A3","protein":"Adenosine receptor A3"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"}],"moaClass":"Adrenergic alpha-Antagonists","modality":"Small Molecule","drugClass":"alpha-Adrenergic Blocker","explanation":"","oneSentence":"","technicalDetail":"Prazosin selectively binds to and blocks the alpha-1A adrenergic receptor, leading to vasodilation and a subsequent decrease in peripheral resistance and blood pressure."},"commercial":{"launchDate":"1976","_launchSource":"DrugCentral (FDA 1976-06-23, PFIZER)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4209","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PRAZOSIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PRAZOSIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:24:55.012612","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:12:03.274792+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"doxazosin","drugSlug":"doxazosin","fdaApproval":"1990-11-02","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"prazosin","indications":{"approved":[{"id":"prazosin-hypertension","name":"Hypertension","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with hypertension","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with hypertension","diagnosticRequired":null,"brandNameForIndication":"Minipress"}],"offLabel":[{"name":"Benign prostatic hyperplasia","source":"DrugCentral","drugName":"PRAZOSIN","evidenceCount":703,"evidenceLevel":"strong"},{"name":"Chronic Post Traumatic Stress Disorder with Trauma-related Nightmares","source":"DrugCentral","drugName":"PRAZOSIN","evidenceCount":29,"evidenceLevel":"moderate"},{"name":"PTSD related nightmares","source":"DrugCentral","drugName":"PRAZOSIN","evidenceCount":82,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Pfizer","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"doxazosin","brandName":"doxazosin","genericName":"doxazosin","approvalYear":"1990","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02266329","phase":"PHASE1,PHASE2","title":"Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-01-04","conditions":["Posttraumatic Headache","Combat Disorders","Post Concussion Syndrome","Headache","Mild Traumatic Brain Injury","Posttraumatic Migraine"],"enrollment":89,"completionDate":"2023-09-30"},{"nctId":"NCT04135846","phase":"PHASE2","title":"Alpha-1 Blockade for Alcohol Use Disorder (AUD)","status":"RECRUITING","sponsor":"Brown University","startDate":"2019-12-19","conditions":["Alcohol Use Disorder (AUD)"],"enrollment":184,"completionDate":"2026-08-31"},{"nctId":"NCT07231978","phase":"PHASE1","title":"A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-11-14","conditions":["Healthy"],"enrollment":72,"completionDate":"2026-05-04"},{"nctId":"NCT06629077","phase":"PHASE2","title":"Brain Blood Vessel Responses to Changes in Blood Flow","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-02-26","conditions":["Magnetic Resonance Imaging","Cerebrovascular Circulation"],"enrollment":36,"completionDate":"2027-01"},{"nctId":"NCT03539614","phase":"PHASE3","title":"Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2018-06-04","conditions":["Posttraumatic Stress Disorder"],"enrollment":87,"completionDate":"2026-06-01"},{"nctId":"NCT06629090","phase":"PHASE2","title":"Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-12-17","conditions":["Magnetic Resonance Imaging","Cerebrovascular Circulation"],"enrollment":36,"completionDate":"2026-12"},{"nctId":"NCT04793685","phase":"PHASE2","title":"Prazosin for Alcohol Use Disorder With Withdrawal Symptoms","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-01","conditions":["Alcohol Withdrawal"],"enrollment":150,"completionDate":"2027-06-30"},{"nctId":"NCT03045016","phase":"PHASE2","title":"Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2017-04-21","conditions":["Acute Stress Disorder"],"enrollment":15,"completionDate":"2020-03-30"},{"nctId":"NCT01437046","phase":"EARLY_PHASE1","title":"Doxazosin an a1 Antagonist for Alcohol Dependence","status":"COMPLETED","sponsor":"Brown University","startDate":"2011-11-01","conditions":["Alcohol Dependence","Anxiety"],"enrollment":41,"completionDate":"2015-03-01"},{"nctId":"NCT05360953","phase":"PHASE2","title":"Treating Nightmares in Posttraumatic Stress Disorder With Clonidine and Doxazosin","status":"SUSPENDED","sponsor":"Charite University, Berlin, Germany","startDate":"2022-06-17","conditions":["Posttraumatic Stress Disorder"],"enrollment":53,"completionDate":"2026-07-31"},{"nctId":"NCT04721353","phase":"PHASE4","title":"Reducing Cannabis Overuse With Prazosin","status":"COMPLETED","sponsor":"VA Puget Sound Health Care System","startDate":"2020-11-09","conditions":["Cannabis Dependence","Posttraumatic Stress Disorder","Cannabis Use Disorder"],"enrollment":11,"completionDate":"2025-06-01"},{"nctId":"NCT03997864","phase":"PHASE4","title":"Administration of Prazosin to Prevent PTSD in Adult Women After Sexual Assault","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2020-02-23","conditions":["Posttraumatic Stress Disorder"],"enrollment":0,"completionDate":"2021-08-20"},{"nctId":"NCT06147622","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2024-04-23","conditions":["Alcohol Use Disorder"],"enrollment":12,"completionDate":"2024-12-31"},{"nctId":"NCT02901977","phase":"PHASE4","title":"Doxazosin and Ramipril in Hypertension","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2011-03","conditions":["Hypertension"],"enrollment":71,"completionDate":"2015-04"},{"nctId":"NCT03410823","phase":"NA","title":"PUSH Plus Protein Pilot for Hip Fracture Patients","status":"TERMINATED","sponsor":"University of Maryland, Baltimore","startDate":"2018-07-16","conditions":["Hip Fracture"],"enrollment":20,"completionDate":"2020-12-12"},{"nctId":"NCT06615440","phase":"","title":"Management and Outcome of Scorpion Sting in Children","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2024-11","conditions":["Scorpion Stings"],"enrollment":70,"completionDate":"2026-10"},{"nctId":"NCT01379898","phase":"PHASE4","title":"Phenoxybenzamine Versus Doxazosin in PCC Patients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-12","conditions":["Pheochromocytoma"],"enrollment":134,"completionDate":"2018-01"},{"nctId":"NCT04967443","phase":"PHASE1","title":"Pivotal Bioequivalence Study to Qualify Manufacturing Site Transfer for Prazosin Hydrochloride Capsules","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-22","conditions":["Hypertension","Heart Failure"],"enrollment":72,"completionDate":"2022-02-15"},{"nctId":"NCT02965027","phase":"PHASE4","title":"Prazosin for Post-Concussive Headaches","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2016-11-29","conditions":["Post-Traumatic Headache"],"enrollment":89,"completionDate":"2023-06-07"},{"nctId":"NCT03339258","phase":"PHASE2","title":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-04-15","conditions":["Stress Disorders, Post-Traumatic"],"enrollment":80,"completionDate":"2024-06"},{"nctId":"NCT00006294","phase":"","title":"Genetics of Hypertension Associated Treatments (GenHAT)","status":"COMPLETED","sponsor":"Donna Arnett, 257-5678","startDate":"1999-09","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Coronary Disease","Myocardial Infarction"],"enrollment":37939,"completionDate":"2005-08"},{"nctId":"NCT04108104","phase":"PHASE2","title":"Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects","status":"COMPLETED","sponsor":"Kinnov Therapeutics","startDate":"2019-11-30","conditions":["Alcohol Use Disorder"],"enrollment":154,"completionDate":"2022-01-31"},{"nctId":"NCT06287905","phase":"PHASE4","title":"A Comparative Study of Using Scorpion Antivenom Versus Scorpion Antivenom and Prazosin","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-02-01","conditions":["Morality"],"enrollment":80,"completionDate":"2024-07-01"},{"nctId":"NCT06282731","phase":"EARLY_PHASE1","title":"The Changes of Urine Growth Factors Level","status":"COMPLETED","sponsor":"En Chu Kong Hospital","startDate":"2013-05-31","conditions":["Benign Prostatic Hyperplasia"],"enrollment":74,"completionDate":"2017-04-27"},{"nctId":"NCT03221751","phase":"PHASE4","title":"Prazosin and Cerebrospinal Fluid (CSF) Biomarkers in Mild Traumatic Brain Injury (mTBI)","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2016-12-01","conditions":["Dementia"],"enrollment":9,"completionDate":"2023-12-05"},{"nctId":"NCT05189977","phase":"PHASE1","title":"A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-09-07","conditions":["Post-traumatic Stress Disorder (PTSD)"],"enrollment":34,"completionDate":"2023-08-03"},{"nctId":"NCT01798992","phase":"PHASE4","title":"Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2000-09","conditions":["Idiopathic Dilated Cardiomyopathy"],"enrollment":56,"completionDate":"2009-03"},{"nctId":"NCT03176693","phase":"PHASE3","title":"Preoperative Alpha Blockade for Pheochromocytoma","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2017-05-05","conditions":["Pheochromocytoma","Paraganglioma"],"enrollment":39,"completionDate":"2021-10-10"},{"nctId":"NCT02364089","phase":"NA","title":"Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2015-04-09","conditions":["Adrenal Incidentalomas"],"enrollment":78,"completionDate":"2022-11-23"},{"nctId":"NCT04280965","phase":"EARLY_PHASE1","title":"Quetiapine Augmentation of PE Therapy for the Treatment of Co-occurring PTSD and Mild Traumatic Brain Injury","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2019-02-01","conditions":["Post Traumatic Stress Disorder"],"enrollment":28,"completionDate":"2022-10-17"},{"nctId":"NCT02616094","phase":"NA","title":"Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse","status":"COMPLETED","sponsor":"Yale University","startDate":"2015-11","conditions":["Alcohol Dependence"],"enrollment":224,"completionDate":"2022-06-30"},{"nctId":"NCT04365257","phase":"PHASE2","title":"Prazosin to Prevent COVID-19 (PREVENT-COVID Trial)","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2020-05-13","conditions":["COVID-19"],"enrollment":5,"completionDate":"2022-03-31"},{"nctId":"NCT03710642","phase":"PHASE2","title":"Prazosin for Agitation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Alzheimer's Disease Cooperative Study (ADCS)","startDate":"2018-10-23","conditions":["Alzheimer's Disease","Disruptive Behavior"],"enrollment":35,"completionDate":"2022-01-05"},{"nctId":"NCT02226367","phase":"NA","title":"Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2015-01","conditions":["Alcohol Use Disorders","Stress Disorders, Posttraumatic","Combat Disorders"],"enrollment":158,"completionDate":"2018-10-20"},{"nctId":"NCT03894345","phase":"PHASE1","title":"Prazosin Use in Adults With Anxiety Disorders","status":"SUSPENDED","sponsor":"University of Manitoba","startDate":"2019-05-24","conditions":["Anxiety","Anxiety Disorders"],"enrollment":20,"completionDate":"2023-12"},{"nctId":"NCT03398252","phase":"PHASE1","title":"Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL","status":"WITHDRAWN","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-05-12","conditions":["Alcohol Use Disorder"],"enrollment":0,"completionDate":"2023-10-01"},{"nctId":"NCT02308202","phase":"PHASE1","title":"DOXAZOSIN FOR PTSD","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-01","conditions":["PTSD"],"enrollment":30,"completionDate":"2014-06-30"},{"nctId":"NCT02538744","phase":"PHASE1","title":"Complementary Combination Therapy for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2015-08","conditions":["Cocaine Dependence"],"enrollment":45,"completionDate":"2018-08-21"},{"nctId":"NCT01783704","phase":"NA","title":"Improving Community Ambulation After Hip Fracture","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2013-06-10","conditions":["Hip Fracture"],"enrollment":210,"completionDate":"2017-10-17"},{"nctId":"NCT04320589","phase":"PHASE2","title":"the Effect of Dexmedetomidine and Magnesium Sulfate in Open Resection of Pheochromocytoma","status":"COMPLETED","sponsor":"National Cancer Institute, Egypt","startDate":"2019-06-30","conditions":["Pheochromocytoma"],"enrollment":30,"completionDate":"2021-08-30"},{"nctId":"NCT02655354","phase":"NA","title":"A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-10","conditions":["Posttraumatic Stress Disorder","Depression","Alcohol-Related Disorders","Suicidal Ideation","Substance-Related Disorders","Mild Cognitive Impairment","Quality of Life","Pain","Wounds and Injury","Brain Injuries","Chronic Disease"],"enrollment":635,"completionDate":"2019-11"},{"nctId":"NCT01030874","phase":"NA","title":"Orthostatic Hypotension Treatment on Rehab Unit","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2011-10","conditions":["Orthostatic Hypotension","Falls"],"enrollment":356,"completionDate":"2016-05"},{"nctId":"NCT04557072","phase":"","title":"Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis","status":"COMPLETED","sponsor":"Jagiellonian University","startDate":"2020-08-01","conditions":["Pheochromocytoma"],"enrollment":1344,"completionDate":"2020-11-02"},{"nctId":"NCT02500602","phase":"PHASE2","title":"CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2016-06-01","conditions":["Posttraumatic Stress Disorder","Alcohol Use Disorders"],"enrollment":144,"completionDate":"2019-12-16"},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":["Hypertension","COVID"],"enrollment":22213,"completionDate":"2020-12-31"},{"nctId":"NCT02989493","phase":"PHASE2","title":"Testing Doxazosin to Treat Stress Mechanisms in Alcoholism","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2017-04-12","conditions":["Alcoholism"],"enrollment":61,"completionDate":"2020-03-13"},{"nctId":"NCT01389609","phase":"PHASE1","title":"Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-07","conditions":["Hypertension"],"enrollment":24,"completionDate":"2011-08"},{"nctId":"NCT02322047","phase":"PHASE2","title":"Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2015-03-03","conditions":["Alcohol Use Disorder","Posttraumatic Stress Disorder (PTSD)"],"enrollment":31,"completionDate":"2018-10-10"},{"nctId":"NCT01518972","phase":"PHASE2","title":"Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2009-09","conditions":["Alcohol Abuse","Posttraumatic Stress Disorder"],"enrollment":30,"completionDate":"2012-06"},{"nctId":"NCT00535925","phase":"PHASE4","title":"Nephropathy In Type 2 Diabetes and Cardio-renal Events","status":"COMPLETED","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2005-10","conditions":["Diabetic Nephropathy"],"enrollment":850,"completionDate":"2019-05"},{"nctId":"NCT00585780","phase":"PHASE1,PHASE2","title":"Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-09","conditions":["Alcohol Dependence"],"enrollment":100,"completionDate":"2019-05-13"},{"nctId":"NCT00762710","phase":"PHASE2","title":"Study of the Medication Prazosin for Alcohol Dependence","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2008-01","conditions":["Alcoholism"],"enrollment":92,"completionDate":"2014-06"},{"nctId":"NCT04371757","phase":"NA","title":"Influence of the Autonomic Nervous System in Response to Exercise in Hypertensive Individuals","status":"UNKNOWN","sponsor":"Instituto de Cardiologia do Rio Grande do Sul","startDate":"2020-04-30","conditions":["Autonomic Nervous System","Hypertension"],"enrollment":39,"completionDate":"2021-12-23"},{"nctId":"NCT00744055","phase":"PHASE3","title":"Prazosin for Treatment of Patients With Alcohol Dependence (AD) and Post Traumatic Stress Disorder (PTSD).","status":"COMPLETED","sponsor":"Yale University","startDate":"2009-01","conditions":["Alcohol Dependence","Stress Disorders, Post-Traumatic"],"enrollment":96,"completionDate":"2014-10"},{"nctId":"NCT02193256","phase":"EARLY_PHASE1","title":"Varenicline + Prazosin for Heavy Drinking Smokers","status":"COMPLETED","sponsor":"Yale University","startDate":"2014-07","conditions":["Cigarette Smoking","Alcohol Use Disorders"],"enrollment":5,"completionDate":"2015-06"},{"nctId":"NCT01953432","phase":"PHASE2","title":"Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2014-04-01","conditions":["Cocaine Dependence"],"enrollment":43,"completionDate":"2017-10-01"},{"nctId":"NCT00922506","phase":"PHASE4","title":"Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-05","conditions":["Overactive Bladder","Benign Prostatic Hyperplasia"],"enrollment":83,"completionDate":"2014-06"},{"nctId":"NCT00880997","phase":"PHASE1","title":"The Efficacy of Doxazosin for Cocaine Users","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-09","conditions":["Cocaine Dependence"],"enrollment":35,"completionDate":"2011-12"},{"nctId":"NCT03416569","phase":"NA","title":"Effects of Prazosin on the Attention-Enhancing Effects of Nicotine","status":"WITHDRAWN","sponsor":"University of Maryland, Baltimore","startDate":"2018-03","conditions":["no Condition, Basic Science"],"enrollment":0,"completionDate":"2019-01"},{"nctId":"NCT01145183","phase":"PHASE2","title":"Pharmacogenetics of Doxazosin for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2010-03","conditions":["Cocaine Dependence"],"enrollment":96,"completionDate":"2015-09"},{"nctId":"NCT02382848","phase":"NA","title":"Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2015-07","conditions":["Stress Disorders, Post-Traumatic","Bulimia Nervosa"],"enrollment":9,"completionDate":"2018-03-09"},{"nctId":"NCT02431936","phase":"PHASE2","title":"Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress","status":"COMPLETED","sponsor":"Augusta University","startDate":"2015-04","conditions":["Hypertension","Stress, Psychological","Blood Pressure"],"enrollment":50,"completionDate":"2019-04-16"},{"nctId":"NCT01999530","phase":"PHASE1","title":"The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2013-11","conditions":["Healthy"],"enrollment":20,"completionDate":"2016-08"},{"nctId":"NCT02966340","phase":"PHASE1,PHASE2","title":"Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2016-11-01","conditions":["Alcoholism"],"enrollment":70,"completionDate":"2018-03-12"},{"nctId":"NCT00487032","phase":"PHASE4","title":"Differential Adrenoreceptor Mediated Tachyphylaxis and Upregulation","status":"COMPLETED","sponsor":"Brian J Lipworth","startDate":"2008-05","conditions":["Allergic Rhinitis","Tachyphylaxis","Rhinitis Medicamentosa"],"enrollment":19,"completionDate":"2009-05"},{"nctId":"NCT01923129","phase":"NA","title":"Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2012-11-30","conditions":["Urinary Retention"],"enrollment":142,"completionDate":"2017-11-22"},{"nctId":"NCT01386177","phase":"PHASE1","title":"Pharmacological Interaction Between Doxazosin and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-07","conditions":["Mood Disorder","Substance-Related Disorders","Amphetamine-Related Disorders"],"enrollment":16,"completionDate":"2012-01"},{"nctId":"NCT00021814","phase":"PHASE3","title":"Medical Therapy of Prostatic Symptoms","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1995-12","conditions":["Prostatic Hyperplasia","Prostatic Hypertrophy, Benign"],"enrollment":3407,"completionDate":"2001-11-30"},{"nctId":"NCT02199652","phase":"PHASE4","title":"Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Augusta University","startDate":"2014-03","conditions":["Post Traumatic Stress Disorder","Suicidal Ideation","Nightmares"],"enrollment":20,"completionDate":"2017-12-01"},{"nctId":"NCT00240227","phase":"NA","title":"Prazosin for ETOH or Cocaine Craving","status":"TERMINATED","sponsor":"US Department of Veterans Affairs","startDate":"2004-04","conditions":["Alcoholism","Cocaine Dependence"],"enrollment":8,"completionDate":"2009-01"},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":["Essential Hypertension","Cardiovascular Disease","Stroke","Chronic Kidney Disease"],"enrollment":21983,"completionDate":"2018-06-30"},{"nctId":"NCT03010995","phase":"PHASE1","title":"The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2018-03-13","conditions":["Cigarette Smoking Toxicity","Nicotine","Acute Cardiovascular Disease"],"enrollment":0,"completionDate":"2018-07-24"},{"nctId":"NCT00202449","phase":"NA","title":"Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2004-07","conditions":["Stress Disorders, Post-Traumatic","Sleep Disorders"],"enrollment":59,"completionDate":"2008-02"},{"nctId":"NCT00183430","phase":"NA","title":"Prazosin for Treating Noncombat Trauma Post-Traumatic Stress Disorder","status":"TERMINATED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2003-10","conditions":["Post-Traumatic Stress Disorder","Sleep Initiation and Maintenance Disorders"],"enrollment":20,"completionDate":"2010-12"},{"nctId":"NCT00990106","phase":"NA","title":"Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2009-09","conditions":["Stress Disorders, Post-Traumatic","Combat Disorders","Sleep Disorders"],"enrollment":67,"completionDate":"2013-03"},{"nctId":"NCT01862497","phase":"","title":"Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-01","conditions":["Intradialytic Hypertension"],"enrollment":76,"completionDate":"2018-04"},{"nctId":"NCT00532493","phase":"PHASE3","title":"Cooperative Studies Program #563 - Prazosin and Combat Trauma PTSD","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2010-01-06","conditions":["PTSD","Sleep Disorders"],"enrollment":304,"completionDate":"2013-05-31"},{"nctId":"NCT01730846","phase":"PHASE2","title":"Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-02","conditions":["Smoking"],"enrollment":35,"completionDate":"2016-11"},{"nctId":"NCT02539810","phase":"PHASE4","title":"Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09","conditions":["Hypertension","Hypertension Resistant to Conventional Therapy","Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 Percent"],"enrollment":4,"completionDate":"2017-07"},{"nctId":"NCT01916941","phase":"NA","title":"Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2013-09","conditions":["Alcohol Use Disorder"],"enrollment":36,"completionDate":"2017-09"},{"nctId":"NCT00223717","phase":"PHASE1","title":"Treatment of Supine Hypertension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2001-01","conditions":["Hypertension"],"enrollment":152,"completionDate":"2017-01"},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":["Prostatic Hyperplasia"],"enrollment":35032,"completionDate":"2010-06"},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":["Prostatic Hyperplasia"],"enrollment":4068,"completionDate":"2010-08"},{"nctId":"NCT01637584","phase":"NA","title":"Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2010-04","conditions":["Non PTSD","PTSD"],"enrollment":40,"completionDate":"2012-11"},{"nctId":"NCT01542372","phase":"PHASE4","title":"Two Stepped Care Models for Posttraumatic Stress Disorder (PTSD) Among Cambodian Refugees With PTSD","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2012-04","conditions":["Posttraumatic Stress Disorder (PTSD)"],"enrollment":114,"completionDate":"2014-03"},{"nctId":"NCT00175682","phase":"NA","title":"Prazosin Vibrostimulation Autonomic Dysreflexia and Spinal Cord Injury Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2004-12","conditions":["Autonomic Dysreflexia"],"enrollment":7,"completionDate":"2011-07-28"},{"nctId":"NCT01178138","phase":"PHASE2","title":"Monoamine Antagonist Therapies for Methamphetamine Abuse Prazosin","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2009-12","conditions":["Continuous Methamphetamine Abuse"],"enrollment":24,"completionDate":"2013-06"},{"nctId":"NCT00393874","phase":"NA","title":"Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2006-10","conditions":["Anxiety Disorders","Mood Disorders","Insomnia","Nightmares"],"enrollment":50,"completionDate":"2011-06"},{"nctId":"NCT01959022","phase":"PHASE4","title":"A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD","status":"COMPLETED","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2013-10","conditions":["Stress Disorders, Post-Traumatic"],"enrollment":15,"completionDate":"2016-06"},{"nctId":"NCT02785393","phase":"PHASE1","title":"DOX as a Potential Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2011-03","conditions":["Substance-Related Disorders"],"enrollment":11,"completionDate":"2016-03"},{"nctId":"NCT00000542","phase":"PHASE3","title":"Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1993-08","conditions":["Cardiovascular Diseases","Coronary Disease","Diabetes Mellitus","Heart Diseases","Hypercholesterolemia","Hypertension","Myocardial Infarction","Myocardial Ischemia","Heart Failure"],"enrollment":0,"completionDate":"2002-03"},{"nctId":"NCT02563405","phase":"PHASE2,PHASE3","title":"The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-09","conditions":["Hypertension"],"enrollment":30,"completionDate":"2018-10"},{"nctId":"NCT02384369","phase":"PHASE2","title":"Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder","status":"WITHDRAWN","sponsor":"Synchroneuron Inc.","startDate":"2016-06","conditions":["Post-Traumatic Stress Disorders","Posttraumatic Stress Disorders","Stress Disorders, Post-Traumatic","Post-Traumatic Stress Disorders, Combat-related"],"enrollment":0,"completionDate":"2017-08"},{"nctId":"NCT00000522","phase":"PHASE2","title":"Treatment of Mild Hypertension Study (TOMHS)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"1985-08","conditions":["Cardiovascular Diseases","Heart Diseases","Hypertension","Vascular Diseases"],"enrollment":0,"completionDate":"1994-05"},{"nctId":"NCT01642433","phase":"PHASE2","title":"Prazosin for Smoking Cessation","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2012-07","conditions":["Nicotine Dependence"],"enrollment":1,"completionDate":"2013-09"},{"nctId":"NCT02369081","phase":"PHASE4","title":"Optimum Treatment for Drug-Resistant Hypertension","status":"UNKNOWN","sponsor":"University of Cambridge","startDate":"2009-05","conditions":["Hypertension, Resistant to Conventional Therapy"],"enrollment":348,"completionDate":"2015-08"},{"nctId":"NCT00141596","phase":"NA","title":"Extracellular Fluid in Resistant Hypertension","status":"TERMINATED","sponsor":"St George's, University of London","startDate":"2003-07","conditions":["Hypertension"],"enrollment":32,"completionDate":"2006-10"},{"nctId":"NCT01126099","phase":"NA","title":"Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease","status":"COMPLETED","sponsor":"Seattle Institute for Biomedical and Clinical Research","startDate":"2010-03","conditions":["Alzheimer's Disease"],"enrollment":20,"completionDate":"2014-03"},{"nctId":"NCT02266537","phase":"PHASE1","title":"Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-11","conditions":["Healthy"],"enrollment":97,"completionDate":""},{"nctId":"NCT01678313","phase":"PHASE2","title":"Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2012-08","conditions":["Benign Prostatic Hyperplasia"],"enrollment":140,"completionDate":"2013-08"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"PRAZOSIN HYDROCHLORIDE"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin HCL"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"prazosin hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Minipress"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin Hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin"},{"form":"CAPSULE","route":"ORAL","productName":"Prazosin Hydrochloride"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147986","MMSL":"2426","NDDF":"000635","UNII":"XM03YJ541D","VUID":"4019901","CHEBI":"CHEBI:8364","VANDF":"4018850","INN_ID":"2593","RXNORM":"203210","UMLSCUI":"C0032912","chemblId":"CHEMBL1558","ChEMBL_ID":"CHEMBL2","KEGG_DRUG":"D00609","DRUGBANK_ID":"DB00457","PDB_CHEM_ID":" XRA","PUBCHEM_CID":"4893","SNOMEDCT_US":"387283005","IUPHAR_LIGAND_ID":"503","SECONDARY_CAS_RN":"19237-84-4","MESH_DESCRIPTOR_UI":"D011224"},"formularyStatus":[],"originalProduct":{"form":"CAPSULE","route":"ORAL","company":"Pfizer Laboratories Div Pfizer Inc","brandName":"Minipress","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1976-","companyName":"Pfizer","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.0 hours","clearance":"4.7 mL/min/kg","bioavailability":"68%","fractionUnbound":"0.06%","volumeOfDistribution":"0.73 L/kg"},"publicationCount":11077,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C02CA01","allCodes":["C02CA01","C02LE01"]},"biosimilarFilings":[],"originalDeveloper":"Pfizer","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":15,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Am Therap","Ani Pharms","Appco","Aurobindo Pharma Ltd","Dava Pharms Inc","Granules","Lannett Co Inc","Mankind Pharma","Msn","Mylan","Novitium Pharma","Purepac Pharm","Teva Pharms","Watson Labs"],"status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1976","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1976-06-23T00:00:00.000Z","mah":"PFIZER","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T03:12:03.274792+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}